Kornimate/medical-research-clean huggingface dataset:
social interactions between people with dementia in nursing home

Conditions: Dementia; Social Interactions

Summary: the aim of this study is to evaluate the direct impact of one session of social stimulation on social interactions of people with moderate dementia living in nursing home in comparison of one session without direct social stimulation.

60 people with moderate dementia living in a french nursing homme participated in this study. residents gave oral consent twice to participate. they were classified in groups of six residents taking into account socio-demographic and medical characteristics. two experimental conditions were proposed : 1. a social stimulation session (36 residents) and 2. a control group without direct social stimulation (24 residents). collected socio-demographic and medical characteristics are age, gender, timf of institutionalization, sociocultural level, marital status and diagnostic hypothesis. before the study, scales and questionnaires were used to assess cognitive status with the mini mental state examination (folstein et al, 1975); functional abilities with instrumental activities of daily living (lawton and brody, 1969); depression with the cornell scale for depression in dementia (alexopoulos et al, 1988); psychological and behavioural disorders with the neuropsychiatric inventory (cummings et al, 1994); and the quality of life with the alzheimer's disease related quality of life (rabins et al, 1999). social interactions are video taped and analyzed in a grid of observation. the aim of the study is to see if there is an impact on social interactions after just one social stimulation session compared to a control group situation. expected results are that residents of the social stimulation group will have more social interactions between us than the resident of the control group.

Eligibility criteria:
inclusion criteria: * presence of a diagnostic of dementia in medical report and a mmse score between 9 and 20. exclusion criteria: * arrival in the institution dating less than six months * invalidating visual or hearing disorders * phasic disorders not allowing a minimum of communication * significant behavioural disorders (which can disturb the meeting) * residents not fluent in french language

Keywords: social interactions dementia social stimulation direct observation
renin-angiotensin aldosterone system and fibrinolysis interaction in humans-specific aim 3

Conditions: Obesity

Summary: the purpose of the study is to determine if giving isosorbide,a drug that is used to treat chest pain, affects blood vessel release of an anti-clotting factor.

to test the hypothesis that the administration of the no donor isosorbide dinitrate,but not the phosphodiesterase inhibitor sildenafil, will attenuate stimulated vascular t-pa release whereas both agents will improve glucose uptake.

Eligibility criteria:
inclusion criteria: * 18-70 years of age * male and female subjects * surgical sterilization * childbearing potential: beta hcg on study day * subjects with a body mass index of 25 or greater exclusion criteria: * diabetes type 1 to type 2 as defined by a fasting glucose of 126 mg/dl or greater or the use of anti-diabetic medication * use of hormone replacement therapy * statin therapy * in hypertensive subjects, a seated systolic blood pressure greater than 179 mmhg or a seated diastolic blood pressure greater than 110 mmhg or taking hypertensives * pregnancy/breast feeding * cardiovascular disease such as myocardial infarction with 6 months prior to enrollment, presence of angina pectoris, significant arrhythmia, congestive heart failure (lv hypertrophy acceptable) deep vein thrombosis, pulmonary embolism, second or three degree heart block, mitral valve stenosis, aortic stenosis, or hypertrophic cardiomyopathy * treatment with anticoagulants * history of serious neurologic disease such as cerebral hemorrhage, stroke or transient ischemic attack * diagnosis of asthma * clinically significant gastrointestinal impairment that could interfere with drug absorption * hematocrit \<35% * hyperlipidemic fasting total cholesterol \>220mg/dl * impaired renal function (serum creatinine \>1.5 mg/dl) * history or presence of immunological or hematological disorders * any underlying or acute disease requiring regular medication which could possible pose a threat to the subject or make implementation of the protocol or interpretation of the study results difficult * impaired hepatic function (serum glutamic oxaloacetic transaminase, serum glutamate pyruvate transaminase \> 60) * treatment with chronic systemic glucocorticoid therapy (more than 7 days in 1 month) * treatment with lithium salts * history of alcohol or drug abuse * treatment with any investigational drug 1 month preceding study * mental conditions rendering the subject unable to understand the nature, scope and possible consequences of the study * inability to comply with the protocol

Keywords: bradykinin obesity nitric oxide donor tissue type plasminogen activator isosorbide dinitrate phosphodiesterase inhibitor renin-angiotensin aldosterone system fibrinolysis angiotensin converting enzyme
optimization of itbs for depression

Conditions: Neuromodulation

Summary: repetitive tms (rtms) is a well-established method for modulating brain activity. through successive stimulations in the form of magnetic fields, it is possible to modify the sensitivity of neurons in the brain, also known as cortical excitability. cortical excitability is important for the induction of brain plasticity, the ability of the brain to reorganize itself and form new connections in response to stimuli. a particular class of rtms, intermittent theta burst tms (itbs), is commonly used to modulate cortical excitability and induce plasticity for therapeutic purposes, notably for treatment-resistant depression. different itbs stimulation parameters can be used to induce plasticity. this study will focus on two parameters, namely, the form and duration of the electromagnetic stimulation. the shape of the electromagnetic pulse refers to how the electromagnetic wave is configured over time, while the duration is simply the period during which this electromagnetic pulse remains active. these parameters are expected to influence the effectiveness of itbs in modulating cortical activity but remain little studied. the main aim of this study will be to compare the effectiveness of different stimulation parameters in the induction of plasticity, which will then make it possible to improve the rtms protocols used for treatment-resistant depression.


Eligibility criteria:
inclusion criteria: * be between 18 and 35 years old * be of right manual dominance * in good health exclusion criteria: * have an implant or pacemaker, * having tinnitus, * have a history of fainting, * have already had an epileptic seizure or have a family history of epilepsy, * have a known neurological disease, * be under psychotropic medication, * have suffered from substance abuse or dependence in the last 6 months, * have a neurostimulator, * have a splinter or metallic implant in the head or the rest of the body, * have a cochlear implant, * have an automated injection system implanted (insulin pump), * have a transdermal patch, * have tattoos in the area to be studied, * be pregnant or breastfeeding,

Keywords: tms repetitive tms intermittent theta burst stimulation plasticity
the effectiveness of diabetic foot wound prevention training

Conditions: Patient Education; Diabetic Foot Ulcer; PechaKucha Method

Summary: this study aimed to evaluate the impact of diabetic foot care training delivered using the pecha kucha (20\*20) presentation method on the knowledge, self-efficacy, and behavior levels of patients with type 2 diabetes. conducted between december 10, 2023, and october 7, 2024, this randomized controlled experimental study included 125 diabetic individuals, with 62 in the experimental group and 63 in the control group. the experimental group received diabetic foot care education using the pecha kucha method, while the control group received conventional education. data were collected using the patient assessment form, diabetes foot knowledge questionnaire, diabetic foot care self-efficacy scale, and foot self-care behavior scale.

this study aimed to evaluate the impact of diabetic foot care training delivered using the pecha kucha (20\*20) presentation method on the knowledge, self-efficacy, and behavior levels of patients with type 2 diabetes. conducted between december 10, 2023, and october 7, 2024, this randomized controlled experimental study included 125 diabetic individuals, with 62 in the experimental group and 63 in the control group. the experimental group received diabetic foot care education using the pecha kucha method, while the control group received conventional education. data were collected using the patient assessment form, diabetes foot knowledge questionnaire, diabetic foot care self-efficacy scale, and foot self-care behavior scale.

Eligibility criteria:
inclusion criteria: * diagnosis of type 2 diabetes according to the american diabetes association (ada) criteria at least six months before the study * age 18 years or older, literacy in and ability to speak turkish, * absence of communication/mental problems, * willingness to participate in the study. exclusion criteria: * presence of advanced retinopathy, violation of inclusion criteria, withdrawal of consent by the patient.

Keywords: pecha kucha type 2 diabetes diabetic foot patient education
study of the efficacy of kalinox® 170 bar in adult oncology

Conditions: Cancer; Pain

Summary: in the oncology practice, the national union of the centres of fight against the cancer recently published the standards, options and recommendations for the coverage of the pains provoked during the invasive gestures of a short duration realized at patients affected by cancer. these support the use of the kalinox ® 170 bar as therapeutic alternative for the preparation of the painful procedures of a short duration such as spinal taps or osseous at the adult.the objective of this study thus is to clarify the appropriate efficiency and the tolerance of the equimolar mixture protoxide of nitrogen / oxygen during invasive procedures realized in adult oncology with regard to the analgesic reference methods and to the effect placebo leads by the accompaniment of the patient during the procedure.


Eligibility criteria:
inclusion criteria: * age \> 18 year * oms between 0 to 3 * patient who has to undergo an invasive gesture or a painful care * absence of contra-indication to the administration of the product exclusion criteria: * patient already included in another incompatible study with this protocol * patient incapable of self-assessment by the eva * confusional syndrome * oms \> 3 * patient already included in this protocol * exclusion criteria linked to the product

Keywords: patient in a oncology unit who has to undergo a painful or invasive procedure
voiding diary video

Conditions: Urinary Incontinence

Summary: the aim of this study is to evaluate patient adherence and completeness of intake and voiding diaries. the secondary goal is to compare the satisfaction and understanding of patients of the intake and voiding trial diaries directions.

this is a randomized prospective study. all women who need to complete an intake and voiding diary at the yale urogynecology outpatient facilities will be invited to participate. after completion of the consent process, they will be randomized to one of two groups. both groups will have their voiding diaries analyzed by three blinded experts and will be graded on completeness of the information filled out. the mean grade obtained from this process and the return rate of the voiding diaries will be the primary outcomes. the secondary outcomes will include a brief patient questionnaire on their satisfaction of the instructions with the voiding diary. the primary and secondary outcomes will be evaluated between the groups to determine the effectiveness of the video intervention.

Eligibility criteria:
inclusion criteria: * need for intake and voiding diary completion * deemed to required return visit or follow up * able to read and write english exclusion criteria: * dementia * prisoners * pregnant patients * medical and physical handicaps which may interfere with completion of intake and voiding diary * medical and physical handicaps with viewing or understanding of the educational video * illiterate patients * patients who cannot speak and understand english
phase iv trial to evaluate breast brachytherapy using the mammosite-ml®

Conditions: Breast Cancer; Ductal Carcinoma in Situ

Summary: this study will evaluate the local control rate, cosmetic results, and complication rates of breast brachytherapy delivered using the mammosite-ml® when used as the sole method of radiation therapy or as a boost technique for patients with stage i-ii carcinoma of the breast (\< 3 cm), (non-lobular histology) treated with lumpectomy with histologically negative surgical margins by at least 2 mm, negative axillary lymph nodes, and dcis. hypotheses: * for selected patients with stage i breast carcinoma and ductal carcinoma in situ (dcis), radiation therapy delivered with brachytherapy alone using the mammosite-ml® is technically feasible and reproducible with acceptable complication rates. * cosmetic results after brachytherapy will be similar to that obtained after traditional whole breast external beam radiation therapy. * local tumor control rate in the breast after brachytherapy will be similar to that of conventional external beam radiation therapy, with less inconvenience and potentially less cost to the patient, given the selection criteria which minimize the risk of clinically significant multicentric or extensive residual carcinoma following lumpectomy.


Eligibility criteria:
inclusion criteria: * women,age of at least 45 years * zubrod performance status of 0-2 * ajcc stage i-ii (t1-t2, n0 m0) breast cancer * maximum tumor dimension \< 3 cm * invasive ductal, medullary, papillary, tubular, colloid (mucinous) histologies * unifocal breast cancer * unilateral breast cancer (no synchronous or previous contralateral breast cancer) * lumpectomy with negative surgical margins by at least 2 mm or re-excision specimen with negative surgical margins by at least 2 mm * ductal carcinoma in-situ * negative axillary lymph nodes for invasive breast cancer (sentinel node biopsy or standard level i-ii dissection with \> 6 nodes removed) * time interval from final breast surgery to brachytherapy loading less than 8 weeks * at least 2 mm of breast tissue between the skin and the mammosite® balloon surface(prefer \> 5 mm) * if chemotherapy is planned, it must begin no earlier that 2 weeks following completion of radiation therapy. if chemotherapy is first, a minimum of 2 weeks from the last cycle must elapse prior to the start of radiation therapy. * signed study-specific consent form exclusion criteria: * invasive lobular histology * non-epithelial breast malignancies such as sarcoma or lymphoma * multifocal or multicentric invasive carcinoma * extensive intraductal component (eic) * paget's disease of the nipple * skin involvement by tumor, regardless of tumor size * positive axillary lymph nodes * distant metastases * collagen vascular disease (scleroderma) * pregnant or lactating women, due to potential exposure of the fetus to rt and unknown effects of rt on lactating females (negative pregnancy test for women of child-bearing age) * any previously treated or synchronous contralateral breast carcinoma * patients with psychiatric or addictive disorder that would preclude obtaining informed consent * men
fluoroscopic anterior approach versus ultrasound guided superior hypogastric plexus neurolysis in cancer pelvic pain

Conditions: Pain Cancer

Summary: cancer related pelvic pain can be debilitating and difficult to treat. superior hypogastric plexus neurolysis (shpn) is considered to be an option for adequately relieving pain, with fewer side effects and improving the quality of life

the superior hypogastric plexus (shp) is one of the paravertebral sympathetic ganglia, located in the lower border of the l5 vertebra and upper part of the sacrum in the retroperitoneal space. it is considered as a continuity of the celiac plexus and the lumbar sympathetic ganglia. it is related to the bifurcation of the aorta and the ureters. the shp has a sympathetic connection (both efferent and afferent fibers) with splanchnic nerves and aortic plexus. it innervates the viscera of the pelvis, including the urinary bladder, ureters, sigmoid colon down to the anal canal, and upper vagina shp blockade can be performed either by ultrasound (us), fluoroscopic, computed tomography (ct) and magnetic resonance imaging (mri) techniques and it is conducted through anterior (transabdominal) or posterior (lateral, paramedian, oblique, transdiscal, or transvaginal) approaches these different imaging modalities and approaches have been described for shpn to make it easier, safer and more accurate and satisfied to the patients

Eligibility criteria:
inclusion criteria: * patients more than 18 years old of both genders with cancer-related pelvic pain, * poor pain control or severe side effects with opioid therapy, * ≥ 4 on a numeric rating scale (nrs) of pain that ranged from 0 (no pain) to 10 (extreme pain)., * american society of anesthesiology physical status class i and ii, * positive diagnostic block day before the procedure by injecting a local anesthetic (0.25% bupivacaine 10 ml) * body mass index ˂ 30 were included in this study. exclusion criteria: * patient refusal, * local or systemic sepsis, * coagulopathy, * unstable cardiovascular and respiratory diseases, * previous neurological deficits, * history of psychiatric disorders, * history of drug abuse, * distorted local anatomy, * those who were allergic to the used medications were excluded from the study.
silver diamine fluoride pilot study (sdf)

Conditions: Dental Caries

Summary: this pilot trial is randomized, double-blind, and placebo-controlled trial with two parallel arms: an intervention group using silver diamine fluoride (sdf) and a placebo group (control). 60 eligible healthy adults will be enrolled in the study and randomly assigned to one of the two treatment groups. both groups will receive the traditional preventive measures including cleanings, fluoride varnish, diet analysis and counseling. study participants will be followed for one year and caries progression will be radiographically monitored.

this pilot study will compare 1) silver diamine fluoride (sdf) and fluoride varnish to 2) placebo and fluoride varnish (conventional prevention) in the management of early approximal carious lesions. early approximal carious lesions refers to decay between teeth, diagnosed with radiographs, not extending more than 1/3 of the way into dentin. management of early approximal carious lesions refers to halting lesion progression, or encouraging lesion reversal after an early carious lesion is detected. sdf provides a novel, low-cost intervention option for managing early carious lesions that could potentially bridge the 'gap' between non-operative and operative options; thus, postponing the first placement of a restoration. sdf has been used in arresting carious lesions for more than 100 years. however, sdf has never been tested in the arrest of approximal caries lesions in permanent teeth. sdf acts to both prevent and arrest tooth decay in multiple ways: 1) it acts on the body of carious lesions by precipitating silver ion into the lesion, thus blocking diffusion pathways for cariogenic acids; 2) it interacts with dental enamel leading to the formation of fluoroapatite crystals making the tooth surface more acid resistant; and 3) the precipitated silver from sdf acts as a bactericidal agent disturbing the formation of cariogenic biofilm.

Eligibility criteria:
inclusion criteria: * presence of at least one approximal caries lesion (scores ra1, ra2, ra3 according to the iccms radiographic scoring system) in one of the posterior teeth (premolars and molars) presented with full contact with the adjacent tooth. * all the surfaces eligible for this study will be included. exclusion criteria: * the approximal lesion detected in the radiograph has advanced dentine lesion (rb4, rc5, or rc6) * or is adjacent to a lesion that is either filled or will receive a filling at the time of enrollment.
chinese acute tissue-based imaging selection for lysis in stroke -tenecteplase

Conditions: Stroke

Summary: to select the best dosage of tenecteplase for acute ischemic stroke patients (onset time 4.5-24h) of large vessel occlusion using early combined ct/mr imaging outcomes


Eligibility criteria:
inclusion criteria: 1. patients presenting with anterior circulation acute ischaemic stroke 2. time from onset to treatment 4.5h-24h 3. patient's age is ≥18 years 4. pre-stroke mrs score of \<= 2 5. clinically significant acute neurologic deficit 6. vessel occlusion or severe stenosis ( ica, mca-m1/m2, aca) on computed tomography angiography (cta)/mra 7. multimodal ct/magnetic resonance imaging: perfusion lesion volume (dt \> 3 s) to infarct core volume ratio (rcbf\ 1.2, absolute difference \>10 ml, and ischemic core volume \<70ml 8. informed consent was obtained from patients. exclusion criteria: 1. intracranial hemorrhage or subarachnoid hemorrhage identified by ct or mri 2. rapidly improving symptoms (patient with an nihss score decrease to \< 4 at randomization) 3. pre-stroke mrs score of \> 2 4. contraindication to imaging with ct/magnetic resonance imaging with contrast agents 5. infarct core \>1/3 middle cerebral artery (mca) territory 6. platelet count \< 100x10\^9/l 7. symptoms were caused by low blood glucose \< 2.7 mmol/l 8. severe uncontrolled hypertension, i.e. systolic blood pressure \>= 180 mmhg or diastolic blood pressure \>=100 mmhg 9. current use of warfarin with a prolonged prothrombin time (inr \> 1.7 or prothrombin time \> 15s) 10. use of low molecular weight heparin within 24 hours 11. use of non-vitamin k antagonist oral anticoagulants (noacs) within 48 hours 12. use of glycoprotein iib - iiia inhibitors within 72 hours. 13. arterial puncture at noncompressible site in previous 7 days 14. major surgery in previous 14 days which poses risk in the opinion of the investigator 15. recent gastrointestinal or urinary tract hemorrhage (within previous 21 days) 16. significant head trauma or prior stroke in previous 3 months 17. history of previous intracranial hemorrhage, intracranial neoplasm, arteriovenous malformation, or aneurysm. risks were considered by the investigator 18. hereditary or acquired haemorrhagic diathesis 19. active internal bleeding 20. symptoms suggestive or recent acute pancreatitis, active gastrointestinal ulcer 21. severe liver disease, including liver failure, cirrhosis, portal hypertension and active hepatitis 22. pregnancy 23. various dying diseases with life expectancy ≤3 months 24. other conditions in which doctors believe that participating in this study may be harmful to the patient 25. patients participated in any observational trial in 30 days 26. allergic to the test drug and its ingredients

Keywords: acute ischemic stroke large vessel occlusion thrombolysis tenecteplase dosage computed tomography magnetic resonance imaging diffusion weighted imaging early combined imaging outcomes modified rankin scale time window beyond 4.5 hours